A Clinical Trial to Determine the Long-term Safety and Tolerability of an Investigational Drug in People With Major Depressive Episode Associated With Bipolar I Disorder (Bipolar I Depression).
Stopped early · Phase 3
Conditions studied: Depressive Episodes, Bipolar I Depression
In brief
This is a clinical trial to determine the long-term safety and tolerability of an investigational drug in people with Major Depressive Episode Associated with Bipolar I Disorder (Bipolar I Depression). Participants in the study will receive the drug being studied. This study is accepting male and female participants between 18 and 65 years old who have completed Study SEP380-301. This study will be conducted in approximately 90 study centers worldwide. The treatment duration for this study is one (1) year.
Key facts
- Study ID
- NCT05227209
- Run by
- Sumitomo Pharma America, Inc.
- People needed
- 64
- Starts
- 2022-03-17
- Expected to finish
- 2023-11-17
- Last updated by the study team
- 2025-02-21
Who can join
Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Subject provides written informed consent and is willing and able to comply with the protocol in the opinion of the Investigator.
- Subject has completed 6 weeks of double-blind treatment and all scheduled assessments from Visit 6/EOT (Day 42) of the lead-in study of SEP-4199 CR.
- Subject is medically appropriate for long-term open-label treatment with SEP-4199 CR in the opinion of the Investigator.
- Female subjects of childbearing potential must agree to use effective and reliable contraception throughout the study and for at least 30 days after the last dose of study drug has been taken. In the Investigator's judgment, the subject will adhere to this requirement.
- Male subjects agree to avoid fathering a child and to use effective methods of birth control throughout the study and until at least 90 days after the last study drug administration.
You may not qualify if…
- Subject is at high risk of non-compliance in the opinion of the Investigator.
- Subject plans to initiate treatment with a prohibited psychotropic medication during the study.
- Subject plans to initiate treatment with transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT), vagus nerve stimulation (VNS), or deep brain stimulation (DBS) during the study.
- Subject experienced a moderate or severe hyperprolactinemia-related AESI in the lead-in study of SEP-4199 CR.
- Subject will require treatment with a drug that is associated with increases in QTc interval.
- Subject had any of the following at Visit 6/EOT (Day 42) of the lead-in study of SEP-4199 CR based on machine reading:
- increase in QTcF interval of ≥ 30 msec AND a QTcF interval ≥ 480 msec, from baseline of the lead-in study of SEP-4199 CR AND a QTCF interval ≥ 480msec
- increase in QTcF interval ≥ 60 msec, from baseline of the lead-in study of SEP-4199 CR
- QTcF interval ≥ 500 msec
- treatment-emergent clinically significant ECG abnormality.
- Subject is considered by the Investigator to be at imminent risk of suicide or injury to self or others, has a MADRS item 10 (suicidal ideation) score ≥ 4, or answers "yes" to "suicidal ideation" item 4 (active suicidal ideation with some intent to act, without specific plan) or item 5 (active suicidal ideation with specific plan and intent) on the C-SSRS assessment at Visit 6/EOT (Day 42) of the lead-in study of SEP-4199 CR.
- Female subject of childbearing potential, has a positive urine pregnancy test at Visit 6/EOT (Day 42) of the lead-in study of SEP-4199 CR or plans to become pregnant during the current study.
- Subject tests positive for any drug of abuse or cannabis at Visit 6/EOT (Day 42) of the lead-in study of SEP-4199 CR
Where it is running
- Advanced Research Center, Inc. — Anaheim, California, United States
- Sun Valley Research Center — Imperial, California, United States
- Clinical innovations, Inc. — Riverside, California, United States
- Collaborative Neuroscience Research, LLC — Torrance, California, United States
- Sarkis Clinical Trials — Gainesville, Florida, United States
- Clinical Neuroscience Solutions, Inc. — Jacksonville, Florida, United States
- Premier Clinical Research Institute, Inc — Miami, Florida, United States
- Clinical Neuroscience Solutions, Inc. — Orlando, Florida, United States
- Atlanta Behavioral Research, LLC — Atlanta, Georgia, United States
- Psych Atlanta, P.C. — Marietta, Georgia, United States
- AMR Conventions Research — Warrenville, Illinois, United States
- St. Charles Psychiatric Associates / Midwest Research Group — Saint Charles, Missouri, United States
- Alivation Research, LLC — Lincoln, Nebraska, United States
- Center for Emotional Fitness — Cherry Hill, New Jersey, United States
- Finger Lakes Clinical Research — Rochester, New York, United States
- Richmond Behavioral Associates ERG Clinical Research - New York PLLC — Staten Island, New York, United States
- New Hope Clinical Research — Charlotte, North Carolina, United States
- Quest Therapeutics of Avon Lake — Avon Lake, Ohio, United States
- Neuro-Behavioral Clinical Research, Inc — North Canton, Ohio, United States
- Sooner Clinical Research — Oklahoma City, Oklahoma, United States
- Lehigh Center for Clinical Research, LLC — Allentown, Pennsylvania, United States
- Community Clinical Research, Inc. — Austin, Texas, United States
- UTHealth Science Center at Houston — Houston, Texas, United States
- Family Psychiatry of The Woodlands — The Woodlands, Texas, United States
- University of Alabama at Birmingham Huntsville Regional Medical Campus — Huntsville, Alabama, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.